<DOC>
	<DOC>NCT00246935</DOC>
	<brief_summary>The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with chronic obstructive pulmonary disease (COPD) who completed the 24-week evaluation of study APTA-2217-06. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is an extension of the 24-week study APTA-2217-06 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.</brief_summary>
	<brief_title>Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Main inclusion criteria: Patients with chronic obstructive pulmonary disease (COPD) Written informed consent Patients who completed the 24week evaluation of study APTA221706 Main exclusion criteria: If patients required hospitalization or received emergency care for COPD exacerbation by the investigator (or subinvestigator) between the informed consent day and the starting day Patients with longterm oxygen therapy Serious diseases</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Phosphodiesterase 4 inhibitor</keyword>
	<keyword>Roflumilast</keyword>
</DOC>